Short QT syndrome no relation quinidine
Short QT syndrome (SQT) is a very rare genetic disease of the electrical system of the heart, and is associated with an increased risk of abnormal heart rhythms and sudden cardiac death. The syndrome gets its name from a characteristic feature seen on an electrocardiogram (ECG) – a shortening of the QT interval.  It is caused by mutations in genes encoding ion channels that shorten the cardiac action potential, and appears to be inherited in an autosomal dominant pattern. The condition is diagnosed using a 12-lead ECG.  Short QT syndrome can be treated using an implantable cardioverter-defibrillator or medications including quinidine.  Short QT syndrome was first described in 2000, and the first genetic mutation associated with the condition was identified in 2004.Other features supporting diagnosis
Other features that support a diagnosis of short QT syndrome include: a history of ventricular fibrillation or ventricular tachycardia despite an apparently structurally normal heart; a family history of confirmed short QT syndrome; a family history of sudden cardiac death aged <40 years; and identification of a genetic mutation consistent with short QT syndrome.Invasive electrophysiological studies, in which wires are passed into the heart to stimulate and record the heart's electrical impulses, are not currently recommended for diagnosing short QT syndrome or predicting the risk of sudden cardiac death.
no relation